NCT05239143View on ClinicalTrials.gov

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

February 15, 2022

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2039

Conditions
Breast CancerOvarian CancerNon Small Cell Lung CancerColorectal CancerPancreatic CancerRenal Cell CarcinomaNasopharyngeal CancerHead and Neck Squamous Cell CarcinomaGastric Cancer
Interventions
BIOLOGICAL

P-MUC1C-ALLO1 CAR-T cells

P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.

DRUG

Rimiducid

Rimiducid (safety switch activator) may be administered as indicated.

Trial Locations (14)

10467

Montefiore Medical Center, The Bronx

21201

University of Maryland Cancer Center, Baltimore

52242

University of Iowa Hospitals and Clinics, Iowa City

66205

University of Kansas Cancer Center, Westwood

67214

Cancer Center of Kansas, Wichita

68198

University of Nebraska Medical Center, Omaha

77030

MD Anderson Cancer Center, Houston

78229

NEXT Oncology, San Antonio

80218

Sarah Cannon Research Institute at HealthONE, Denver

90048

Cedars Sinai Medical Center, Los Angeles

92037

University of California, San Diego, San Diego

92868

University of California, Irvine Medical Center, Irvine

94143

University of California, San Francisco, San Francisco

02215

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Poseida Therapeutics, Inc.

INDUSTRY

NCT05239143 - P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter